The 2026 ASCO Annual Meeting featured a series of practice-informing presentations across the myeloid malignancies spectrum. Among them, data on Mesutoclax (ICP-248), a novel BCL2 inhibitor, in combination with azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were selected for oral presentation, drawing notable clinical interest. The study not only showed promising efficacy of Mesutoclax but also highlighted meaningful benefits in terms of safety and its overall pharmaceutical profile.
In this exclusive interview with MedJ, Prof. Amer Zeidan of Yale School of Medicine—who served as session chair for the Myeloid Malignancies track at ASCO—provides his expert perspective on the unmet needs in higher-risk MDS and AML, the clinical profile of Mesutoclax, and its potential role in evolving treatment paradigms.
Major Debut: Mesutoclax Stands Out with Oral Presentation Selection at ASCO
Med J:You just chaired a session featuring an oral presentation on mesutoclax plus azacitidine –an honor given to less than 9% of abstracts. What elevated this dataset to oral presentation status? And what should our listeners take away from the session?
Dr. Amer Zeidan:
Oral presentations are usually given to the abstracts that have the highest clinical impact or the highest scientific value. In our session covering advances across all myeloid cancers, the abstract looking at mesutoclax had very good data and was very well received. As a novel, potent, and highly selective oral BCL2 inhibitor, mesutoclax exhibits a favorable pharmacokinetic profile without any major metabolites. In this reported global Phase I study (ICP-CL-01205, NCT06656494), its safety and efficacy in combination with azacitidine were evaluated in AML and MDS patients, successfully identifying 100 mg and 125 mg as the recommended doses for expansion (RDE). The study has demonstrated preliminary efficacy signals across both frontline and relapsed settings for AML and MDS.
Addressing Unmet Needs in Higher-Risk MDS: Two Decades of Therapeutic Challenges and the Quest for New Standards
MedJ:Azacitidine has been the standard of care for higher-risk MDS for over a decade. But the composite CR rate is only about 16%, and median survival is still measured in months. Why hasn't the field moved beyond it? And what causes most patients to fail to achieve durable remission?
Dr. Amer Zeidan:
The field has been very anxious to get new drugs with good efficacy and safety data to move into the front line setting. Past clinical trials in high-risk MDS have frequently stumbled, largely due to two factors. First, flawed trial endpoints, which overemphasized marrow complete remission without sustained count recovery, falling short of true clinical benefit. Second, the challenge of refractory subsets; for instance, patients harboring TP53 mutations are notoriously resistant to existing standard therapies. If a new drug fails to demonstrate efficacy in this highly challenging subgroup, it often drags down the overall trial outcomes.
I have high expectations for mesutoclax because it provides a biological breakthrough. It effectively avoids inhibition of BCL-XL, and its metabolites do not stick around in the circulation for a long time, significantly reducing prolonged myeloid suppression.
Early clinical data showed that these mechanistic advantages are translating into significant clinical benefits. In the frontline setting, an overall response rate (ORR) around 90% with most achieving count recovery. Furthermore, it has even demonstrated preliminary efficacy signals in the notoriously difficult-to-treat TP53-mutated subgroup.
For high-risk MDS patients, who are often elderly and frail, this excellent safety and tolerability is absolutely critical for long-term maintenance therapy. Coupled with its once-daily oral dosing regimen, it greatly enhances the convenience of clinical management and patient compliance.
MedJ:After azacitidine fails, no FDA-approved therapy exists for HR-MDS patients. Not one. How many such patients are there? What is their life like today? And why has this gap remained empty for so long?
Dr. Amer Zeidan:
In the US, at least 20,000 cases are diagnosed with MDS each year, with around half being higher-risk disease. This number is going to increase due to an aging population and a substantial number of therapy-related cases from previous cancer treatments. For many years, we still do not have new drugs beyond azacitidine, and combining other drugs often caused severe myelosuppression and infectious complications. Mesutoclax could be very important as tolerability and myelosuppression are not as big of an issue. In the treatment-naive AML cohort, the ORR was over 80% and the complete response (CR) was 63.6%, with a low risk of infections and almost zero 30-day and 60-day early mortality, which is highly valuable for patients susceptible to complications.
Efficacy Insights: What Drives High-Quality Responses with Mesutoclax in MDS?
MedJ:Why should a BCL2 inhibitor work in MDS? What makes HR-MDS cells depend on BCL2? And why is BCL2 inhibition a compelling strategy here?
Dr. Amer Zeidan:
Biologically, high-risk MDS and AML share a high degree of homology. In both diseases, the abnormal proliferation of cancer cells leads to a significant increase in the expression of pro-apoptotic proteins. To evade cell death, these cancer cells compensatorily upregulate the expression of the anti-apoptotic factor BCL2, forming an inherent survival and resistance mechanism. Therefore, by targeting and inhibiting the BCL2 pathway, we can effectively restart the apoptotic program of these cancer cells, which translates into substantial clinical benefits.
Given that AML and high-risk MDS are closely related—both characterized by increased blast count and pro-apoptotic proteins—and this approach has been proven to increase response rates and survival in AML, the mechanism makes complete sense in MDS. Supported by rigorous trial designs, innovative targeted therapies with immense breakthrough potential that better address clinical pain points, such as mesutoclax, hold the promise of fundamentally improving outcomes for higher-risk MDS patients and truly filling this long-standing clinical void.
MedJ:The high-risk MDS results for mesutoclax plus azacitidine are striking. How do you interpret these efficacy data? And what do they suggest for the mesutoclax drug's future in MDS?
Dr. Amer Zeidan:
Patients in the very high-risk and high-risk groups as defined by the IPSS-R tend to face the most dire prognoses and represent the population in most urgent need of innovative therapies. Although from a relatively small sample size, mesutoclax showed a positive trend with a CR of 40% and an overall response rate of 100%. Crucially, the majority of responding patients met the latest IWG 2023 criteria, achieving meaningful blood count recovery. This high-quality hematologic recovery is vital; it not only drastically reduces the risk of complications from infections and severe bleeding but also lays a solid foundation for translating into durable responses and long-term survival benefits. Additionally, we have observed positive clearance signals at the measurable residual disease (MRD) level. Taken together across multiple efficacy dimensions, the drug's profile demonstrates exceptionally high clinical translational potential.
From MDS to AML: Promising Data in Treatment-Naïve AML and Early Signals in the Relapsed/Refractory Setting
MedJ:If venetoclax already works in AML, what's the scientific case for mesutoclax?
Dr. Amer Zeidan:
While previous targeted therapies led to improvements, clinical problems remain: non-responders, limited median survival, frequent relapses, and certain subsets like TP53-mutated patients struggling to benefit. On the safety front, existing combinations can be myelosuppressive, causing infections, bleeding, and early mortality risks. Mesutoclax could address issues on both the efficacy and safety fronts: in a cohort of over 40 treatment-naive patients, it achieved a 63.6% CR rate and an ORR >80%, with responses seen even in adverse cytogenetic groups. On safety, there were no treatment-related deaths in the first 60 days, and the time to count recovery looked better, presenting a stable profile. This could be partly explained by its lack of BCL-XL inhibition, which spares platelets. Moreover, it has minimal food interactions and minimal drug-drug interactions, greatly reducing the burden of intense clinical monitoring, making it a promising new standard of care candidate for both AML and high-risk MDS.
MedJ:Currently, for newly diagnosed elderly patients with acute myeloid leukemia (AML) or those unfit for intensive chemotherapy, azacitidine plus venetoclax (AZA+VEN) is a commonly used standard regimen in this field. Against this background, what insights does the recently released data on Mesutoclax in combination with azacitidine offer us?
Dr. Amer Zeidan:
Among the 35 evaluable treatment-naive AML patients, the centrally assessed complete remission (CR) rate reached 63.6%, and the composite CR (cCR) rate was as high as 81.8%. This shows that the profile on the efficacy front presents a highly positive signal. As I mentioned, seeing more sustained count recovery is a very important clinical evaluation point, carrying significance well beyond merely reducing the blasts.
MedJ:For relapsed/refractory AML, especially in patients who have progressed on prior therapies, what did mesutoclax show? Can BCL2 inhibition still be a viable pathway?
Dr. Amer Zeidan:
In the latest Phase I clinical data presented at this conference, the cohort included patients with relapsed/refractory (R/R) AML. In clinical practice, most of these patients had prior exposure to frontline targeted therapies. Once they relapse or develop resistance, their prognosis is generally extremely poor, with an expected survival of only four to six months, and they currently face a treatment dead-end with no approved targeted therapies available. However, mesutoclax demonstrated promising potential even in this dire setting and among patients with poor genetic profiles, achieving objective responses including complete CRs. The data is looking quite good, presenting positive signals. Currently, we have also started enrolling a refractory/relapsed higher-risk MDS cohort at our US center, and we are very excited to see the potential clinical benefits for these patients.
Safety as a Core Differentiator: 0 Early Deaths, Transient Cytopenias, and No DLTs
MedJ:Safety and tolerability are critical considerations when evaluating new therapies for AML/MDS patients. In this Phase 1 study of 78 patients, we saw no DLTs, the MTD was not reached, and the 30/60-day mortality was zero in treatment-naive AML. Furthermore, the duration of Grade 4 neutropenia and thrombocytopenia was notably brief—only 10 and 6 days, respectively. What is the biological mechanism driving this safety profile, and how might these characteristics translate into clinical practice?
Dr. Amer Zeidan:
A significant reduction in early mortality usually reflects the effective mitigation of the risks of severe infection, prolonged myelosuppression, and febrile neutropenia. Mesutoclax's ability to exhibit this stable safety profile comes very nicely from its distinct biological rationale and higher potency. Its metabolites do not stick around longer in the circulation, contributing to a lower risk of prolonged myelosuppression; furthermore, it does not seem to hit BCL-XL, which avoids leading to thrombocytopenia. This scientific drug design basically explains the initial clinical safety benefits we are seeing. I anticipate and hope to see longer durability of responses and hence a prolonged survival, which will be critical for this drug to completely differentiate itself in its development pathway and hopefully get approved.
Expert Biography

Amer Zeidan
Professor of Internal Medicine
Chief, Division of Hematological Malignancies
Assistant Medical Director, Hematology, Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Medical Oncology and Hematology, Department of Internal Medicine
Yale School of Medicine and Yale Comprehensive Cancer Center
References
Wang H, Jiang Q, Zhao X, et al. Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies. ASCO 2026:abstr 6506.